Biotech Values

[mcbio]

So VRUS has all promising interferon-sparing combos: all nukes, nuke + NS5A, and now nuke+PI.

I wouldn't say that they have the latter two combos just yet. The deals with BMY and Tibotec are merely clinical trial collaborations. Assuming the trials yield results, I imagine some formal licensing deals will be struck afterwards between the companies, if one of them doesn't outright acquire VRUS.